Harry Struijker-Boudier

Harry Struijker-Boudier
Occupation(s)Cardiovascular pharmacologist and academic
Academic background
EducationGraduation
Doctor of Philosophy
Alma materRadboud University Nijmegen
Academic work
InstitutionsMaastricht University

Harry Struijker-Boudier is a cardiovascular pharmacologist and academic. He is an emeritus professor of Pharmacology at Maastricht University.

Struijker-Boudier's research has been focused in the areas of cardiovascular disease, pharmacological science, and pharmacotherapy. He has received the Saavan Zwanenberg Honorary Prize, an honorary doctorate from the University of Liège, Belgium, and Prix Descartes-Huygens from the French Académie des Sciences. He was also appointed an Officer of the Order of Orange-Nassau of the Dutch Royal House in 2010.

Education

Struijker-Boudier completed his graduation in Pharmacochemistry and Biochemistry and Doctor of Philosophy in Pharmacology from the Radboud University Nijmegen in 1973 and 1975, respectively.[1]

Career

At the University of Maastricht Medical School, Struijker-Boudier held the role of professor of Experimental Pharmacology and chaired the Department of Pharmacology and Toxicology. He was also designated as a scientific director of the Cardiovascular Research Institute Maastricht.[1] He is the chairman of the scientific board of the Paris Cardiovascular Research Center and the Nancy Cardiovascular Research Center. He also holds the title of emeritus professor at Maastricht University.[2]

Research

During his early research studies, Struijker-Boudier highlighted the vascular origin of hypertension,[3] in particular at the level of the microcirculation.[4] In a later follow-up, together with Le Noble and Levy, he showed that VEGF (Vascular Endothelial Growth Factor) inhibitors cause hypertension.[5] His research also highlighted that dysfunctional microcirculation is a key shared mechanism that induces diabetes and hypertension.[6][7]

Together with Kool and Van Bortel, Struijker-Boudier documented that smoking, even one cigarette, increases arterial stiffness and augments the risk of cardiovascular diseases and stroke.[8][9] In another collaborative study, he emphasized that arterial aging is not uniform; muscular arteries change less with age, whereas central arteries stiffen significantly.[10] Furthermore, he examined the clinical implications of arterial stiffness, specifically its role in predicting cardiovascular diseases.[11] In addition, he discussed appropriate assessment methods for arterial stiffness, emphasizing the shift to more direct measures, such as carotid-femoral pulse wave velocity (PWV) and augmentation index.[12]

Awards and honors

Selected articles

  • Levy, B. I.; Ambrosio, G.; Pries, A. R.; Struijker-Boudier, H. A. J. (2001). "Microcirculation in hypertension: a new target for treatment?". Circulation. 104 (6): 735–740. doi:10.1161/hc3101.091158. PMID 11489784.
  • Safar, M. E.; Levy, B. I.; Struijker-Boudier, H. (2003). "Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases". Circulation. 107 (22): 2864–2869. doi:10.1161/01.CIR.0000069826.36125.B4. PMID 12796414.
  • Laurent, S.; Cockcroft, J.; Van Bortel, L.; Boutouyrie, P.; Giannattasio, C.; Hayoz, D.; Struijker-Boudier, H. (2006). "Expert consensus document on arterial stiffness: methodological issues and clinical applications". European Heart Journal. 27 (21): 2588–2605. doi:10.1093/eurheartj/ehl254. PMID 17000623.
  • Levy, B. I.; Schiffrin, E. L.; Mourad, J. J.; Agostini, D.; Vicaut, E.; Safar, M. E.; Struijker-Boudier, H. A. (2008). "Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus". Circulation. 118 (9): 968–976. doi:10.1161/CIRCULATIONAHA.107.763730. PMID 18725503.
  • Mancia, Giuseppe; Laurent, Stéphane; Agabiti-Rosei, Enrico; Ambrosioni, Ettore; Burnier, Michel; Caulfield, Mark J.; Cifkova, Renata; Clément, Denis; Coca, Antonio; Dominiczak, Anna; Erdine, Serap; Fagard, Robert; Farsang, Csaba; Grassi, Guido; Haller, Hermann; Heagerty, Antony; Kjeldsen, Sverre E.; Kiowski, Wolfgang; Mallion, Jean Michel; Manolis, Athanasios; Narkiewicz, Krzysztof; Nilsson, Peter; Olsen, Michael H.; Rahn, Karl Heinz; Redon, Josep; Rodicio, José; Ruilope, Luis; Schmieder, Roland E.; Struijker-Boudier, Harry A.J.; Van Zwieten, Pieter A.; Viigimaa, Margus; Zanchetti, Alberto (2009). "Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document". Blood Pressure. 18 (6): 308–347. doi:10.3109/08037050903450468. PMID 20001654.

References

  1. ^ a b "Dr Harry Struijker-Boudier". Dove Press. Retrieved June 25, 2025.
  2. ^ "Scientific Director–Cardiology". Medea academy. 26 April 2022. Retrieved June 25, 2025.
  3. ^ Pandey, Arvind K.; Singhi, Eric K.; Arroyo, Juan Pablo; Ikizler, Talat Alp; Gould, Edward R.; Brown, Jonathan; Beckman, Joshua A.; Harrison, David G.; Moslehi, Javid (February 2018). "Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease". Hypertension (Dallas, Tex.: 1979). 71 (2): e1 – e8. doi:10.1161/HYPERTENSIONAHA.117.10271. PMC 5825002. PMID 29279311.
  4. ^ Chua, Jacqueline; Tan, Bingyao; Wong, Damon; Garhöfer, Gerhard; Liew, Xin Wei; Popa-Cherecheanu, Alina; Loong Chin, Calvin Woon; Milea, Dan; Li-Hsian Chen, Christopher; Schmetterer, Leopold (2024). "Optical coherence tomography angiography of the retina and choroid in systemic diseases". Progress in Retinal and Eye Research. 103 101292. doi:10.1016/j.preteyeres.2024.101292. PMID 39218142.
  5. ^ Kuang, Hongyu; Yan, Qingkai; Li, Zhanzhi; Lin, Anqi; Li, Kailai; Zhang, Jian; Luo, Peng; Yin, Yuehui (2024). "Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models". Frontiers in Immunology. 15 1488853. doi:10.3389/fimmu.2024.1488853. PMC 11534862. PMID 39502700.
  6. ^ Climie, Rachel E.; van Sloten, Thomas T.; Bruno, Rosa-Maria; Taddei, Stefano; Empana, Jean-Philippe; Stehouwer, Coen D. A.; Sharman, James E.; Boutouyrie, Pierre; Laurent, Stéphane (June 2019). "Macrovasculature and Microvasculature at the Crossroads Between Type 2 Diabetes Mellitus and Hypertension". Hypertension (Dallas, Tex.: 1979). 73 (6): 1138–1149. doi:10.1161/HYPERTENSIONAHA.118.11769. PMID 31067192.
  7. ^ Chua, Jacqueline; Tan, Bingyao; Wong, Damon; Garhöfer, Gerhard; Liew, Xin Wei; Popa-Cherecheanu, Alina; Loong Chin, Calvin Woon; Milea, Dan; Li-Hsian Chen, Christopher; Schmetterer, Leopold (November 2024). "Optical coherence tomography angiography of the retina and choroid in systemic diseases". Progress in Retinal and Eye Research. 103 101292. doi:10.1016/j.preteyeres.2024.101292. PMID 39218142.
  8. ^ Goldstein, L. B.; Adams, R.; Becker, K.; Furberg, C. D.; Gorelick, P. B.; Hademenos, G.; Hill, M.; Howard, G.; Howard, V. J.; Jacobs, B.; Levine, S. R.; Mosca, L.; Sacco, R. L.; Sherman, D. G.; Wolf, P. A.; del Zoppo, G. J. (2 January 2001). "Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association". Circulation. 103 (1): 163–182. doi:10.1161/01.cir.103.1.163. PMID 11136703.
  9. ^ Goldstein, Larry B.; Adams, Robert; Alberts, Mark J.; Appel, Lawrence J.; Brass, Lawrence M.; Bushnell, Cheryl D.; Culebras, Antonio; Degraba, Thomas J.; Gorelick, Philip B.; Guyton, John R.; Hart, Robert G.; Howard, George; Kelly-Hayes, Margaret; Nixon, J. V. Ian; Sacco, Ralph L. (June 2006). "Primary prevention of ischemic stroke". Stroke. 37 (6): 1583–1633. doi:10.1161/01.STR.0000223048.70103.F1. PMID 16675728.
  10. ^ Mitchell, Gary F.; Parise, Helen; Benjamin, Emelia J.; Larson, Martin G.; Keyes, Michelle J.; Vita, Joseph A.; Vasan, Ramachandran S.; Levy, Daniel (June 2004). "Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study". Hypertension (Dallas, Tex.: 1979). 43 (6): 1239–1245. doi:10.1161/01.HYP.0000128420.01881.aa. PMID 15123572.
  11. ^ Van Bortel, Luc M.; Laurent, Stephane; Boutouyrie, Pierre; Chowienczyk, Phil; Cruickshank, J. K.; De Backer, Tine; Filipovsky, Jan; Huybrechts, Sofie; Mattace-Raso, Francesco U. S.; Protogerou, Athanase D.; Schillaci, Giuseppe; Segers, Patrick; Vermeersch, Sebastian; Weber, Thomas (March 2012). "Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity". Journal of Hypertension. 30 (3): 445–448. doi:10.1097/HJH.0b013e32834fa8b0. hdl:1765/73145. PMID 22278144.
  12. ^ Mitchell, Gary F.; Hwang, Shih-Jen; Vasan, Ramachandran S.; Larson, Martin G.; Pencina, Michael J.; Hamburg, Naomi M.; Vita, Joseph A.; Levy, Daniel; Benjamin, Emelia J. (2 February 2010). "Arterial stiffness and cardiovascular events: the Framingham Heart Study". Circulation. 121 (4): 505–511. doi:10.1161/CIRCULATIONAHA.109.886655. PMC 2836717. PMID 20083680.
  13. ^ a b "Harry A.J. Struijker-Boudier". Scientific Seminars. 4 March 2022. Retrieved August 4, 2025.
  14. ^ "Prix Descartes-Huygens/Descartes-Huygensprijs" (PDF). Académie des sciences. Retrieved June 25, 2025.
  15. ^ "KHMW Dr. Saal van Zwanenberg Honorary Award". Koninklijke Hollandsche Maatschappij der Wetenschappen. Retrieved June 25, 2025.

Harry Struijker-Boudier publications indexed by Google Scholar

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.